Starpharma (ASX:SPL) Announces Q3 FY25 Activities Report
Operational Achievements
Starpharma demonstrated momentum in its partnering efforts, confirming clinical pathway options for DEP® SN38 based on FDA feedback. The one-year partnership with Medicxi to form Petalion Therapeutics has generated research revenue and remains a key focus for the discovery team. The company launched its Star Navigator program and participated in BIO Europe-Spring, showcasing the DEP® platform technology.
Product Launches
Starpharma launched VivaGel® BV in Saudi Arabia and the United Arab Emirates, initiated a new Viraleze™ advertising campaign in the UK, and received first Viraleze™ orders for Saudi Arabia.
Financial Performance
As of 31 March 2025, Starpharma held a cash balance of $17.2 million. Cash payments from operating activities for the quarter were $4.1 million, while receipts from customers increased to $1.4 million compared to $0.4 million in Q3 FY24.
Research Collaborations
Celebrating one year since partnering with Medicxi to form Petalion Therapeutics, the collaboration has significantly progressed, generating research revenue and focusing the discovery team.
Strategic Priorities
A recent Board strategy meeting reaffirmed strategic priorities: maximising DEP® asset value, accelerating early asset development, focusing on DEP® radiopharmaceuticals, and building long-term sustainability.
Executive Comments
CEO Cheryl Maley stated, “It is almost 12 months since we announced our revised strategy. We have made significant progress towards achieving our objectives during this time, and we acknowledge that some outcomes are taking longer than we initially anticipated. The Starpharma team remains intensely focused on delivering on our strategic priorities, and we are committed to achieving the outcomes agreed with the Board in May 2024 with a high sense of urgency. Earlier this month, the Board and Leadership team convened to reflect on Starpharma’s progress and to reaffirm our strategic direction going forward. Our top priorities this quarter have been to advance existing and potential new partnerships, develop the clinical program for DEP® SN38 to get to market in the most time- and commercially-effective way and build robust pre-clinical data in our radio program that exemplifies the benefits of our dendrimer technology in radiopharmaceuticals. … I would like to thank our shareholders for your patience and ongoing support as we work diligently to restore value to Starpharma investors.”
Motley Fool contributor Aaron Shaw has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
